

1 JOHN J. SHAEFFER (SBN 138331)  
jshaeffer@foxrothschild.com  
2 Meeghan H. Tirtasaputra (SBN 325572)  
mtirtasaputra@foxrothschild.com  
3 FOX ROTHSCHILD LLP  
10250 Constellation Boulevard, Suite 900  
4 Los Angeles, California 90067  
Telephone: 310-598-4150  
5 Facsimile: 310-556-9828  
6 Attorneys for Plaintiff  
STARQUEST VENTURES, INC.  
7  
8

9 UNITED STATES DISTRICT COURT  
10 CENTRAL DISTRICT OF CALIFORNIA  
11 WESTERN DIVISION  
12

13 STARQUEST VENTURES INC. dba  
14 Stelo, a California Corporation,

15 Plaintiff,

16 v.

17 DEXCOM, INC., a Delaware Corporation;  
18 and DOES 1-10, inclusive,

19 Defendants.  
20  
21  
22

Case No.: 2:25-cv-05470-AH-JPR  
Hon. Anne Hwang

**DECLARATION OF MEEGHAN H.  
TIRTASAPUTRA IN SUPPORT OF  
PLAINTIFF STARQUEST  
VENTURES INC.'S MOTION FOR  
PRELIMINARY INJUNCTION**

*[Filed concurrently with Notice of  
Motion and Motion; Memorandum of  
Points and Authorities; Declarations of  
Paul Rampel, Jessica Sheridan, and  
Kimberly B. Gatling; Compendium of  
Exhibits; Notice of Lodging; and  
[Proposed] Order]*

Date: July 30, 2025  
Time: 1:30 pm  
Place: Courtroom 7D

Action Filed: June 16, 2025  
Trial Date: None Set

**DECLARATION OF MEEGHAN H. TIRTASAPUTRA**

I, Meeghan H. Tirtasaputra, state and declare as follows:

1. I am an attorney duly licensed to practice law in the State of California and admitted to practice in the Central District of California. I make this declaration in support of Plaintiff StarQuest Ventures, Inc.’s Motion for Preliminary Injunction in the above-captioned matter. I make this declaration of my own personal knowledge and could and would so testify if called.

2. Attached as Exhibit 3 to the Compendium of Exhibits is a true and correct copy of the 2024 Dexcom Annual Report.

3. Attached as Exhibit 4 to the Compendium of Exhibits is a true and correct copy of the 510(k) Substantial Equivalence Determination Decision Summary.

4. Attached as Exhibit 5 to the Compendium of Exhibits is a true and correct copy of an FDA News Release dated March 5, 2024, FDA Clears First Over-the-Counter Continuous Glucose Monitor.

5. Attached as Exhibit 6 to the Compendium of Exhibits is a true and correct copy of US Trademark Application Serial No. 98274053 (STELO), Application filed on November 16, 2023.

6. Attached as Exhibit 7 to the Compendium of Exhibits is a true and correct copy of a news blogpost by DexCom, Inc. Investors News entitled, “Stelo by Dexcom First Glucose Biosensor Cleared by FDA as Over-the-Counter”, dated March 5, 2024.

7. Attached as Exhibit 8 to the Compendium of Exhibits is a true and correct copy of the Stelo User Guide Revised March 2025.

8. Attached as Exhibit 9 to the Compendium of Exhibits is a true and correct copy of a screenshot of the Stelo by Dexcom App on Google Play.

///

1           9. Attached as Exhibit 10 to the Compendium of Exhibits is a true and  
2 correct copy of a screenshot of the homepage of Stelo.com as created by Dexcom.

3           10. Attached as Exhibit 11 to the Compendium of Exhibits is a true and  
4 correct copy of a Time Magazine article entitled “The Best Inventions of 2024,”  
5 featuring Dexcom’s Stelo Monitor.

6           11. Attached as Exhibit 12 to the Compendium of Exhibits is a true and  
7 correct copy of an article from The Verge entitled “This over-the-counter gadget  
8 could help the war against diabetes,” featuring Dexcom’s Stelo Monitor.

9           12. Attached as Exhibit 13 to the Compendium of Exhibits is a true and  
10 correct copy of an article from The Verge entitled “Dexcom’s new continuous  
11 glucose monitor is a health tech gadget with purpose,” featuring Dexcom’s Stelo  
12 Monitor.

13           13. Attached as Exhibit 14 to the Compendium of Exhibits is a true and  
14 correct copy of an article from the Journal of Multidisciplinary Healthcare, entitled  
15 “Continuous Glucose Monitoring: A Transformative Approach to the Detection of  
16 Prediabetes,” featuring Dexcom’s Stelo Monitor.

17           14. Attached as Exhibit 15 to the Compendium of Exhibits is a true and  
18 correct copy of the first ten pages of a Google search of the term “Stelo.”

19           15. Attached as Exhibit 16 to the Compendium of Exhibits is a true and  
20 correct copy of Dexcom’s Form 10-Q, Quarterly Report Ended March 31, 2025 filed  
21 with the United States Securities and Exchange Commission.

22           16. Attached as Exhibit 17 to the Compendium of Exhibits is a true and  
23 correct copy of a powerpoint presentation by Dexcom entitled “Dexcom’s Earnings  
24 Q1 2025.”

25 ///

26 ///

27 ///

